Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) CEO David Elsley talks to Proactive about the Oakville, Ontario-based group's clinical studies aimed at treating inflammatory heart disease. Elsley says its recently completed Phase 1 study with CardiolRx supports its Phase II/III COVID-19 trial in patients with prior history of, or risk factors for, cardiovascular disease and the filing of its IND application with the FDA for an international Phase II trial in acute myocarditis.
Cardiol Therapeutics CEO discusses its clinical studies aimed at heart disease and the coronavirus
Quick facts: Cardiol Therapeutics
Price: 5.69 CAD
Market Cap: $244.37 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE